Allergen immunotherapy for long-term tolerance and prevention

Area of Science:

• Clinical immunology
• Allergy and immunology
• Pharmacology

Background:

• Allergen immunotherapy (AIT) is a treatment for allergic conditions.
• Long-term benefits after AIT discontinuation are crucial to evaluate due to cost and patient commitment.
• Existing evidence on sustained clinical efficacy and immune changes post-treatment needs appraisal.

Purpose of the Study:

• To review the long-term effects of subcutaneous and sublingual immunotherapy.
• To assess clinical efficacy, immune mechanisms, and preventive effects on asthma and new sensitizations.
• To inform treatment duration recommendations for sustained benefits.

Main Methods:

• Systematic review of randomized, double-blind, placebo-controlled trials with follow-up phases.
• Analysis of data on clinical outcomes, immunological changes, and asthma development.
• Evaluation of evidence for grass pollen and mite allergen immunotherapy.

Main Results:

• Evidence from robust clinical trials supports long-term efficacy of AIT after treatment cessation.
• A minimum treatment duration of 3 years for both subcutaneous and sublingual immunotherapy is supported by international guidelines.
• Grass pollen immunotherapy may prevent asthma onset, but early intervention with mite immunotherapy in infants requires further investigation.

Conclusions:

• Allergen immunotherapy provides persistent clinical benefits, justifying its use.
• Extended treatment duration (≥3 years) is essential for disease modification and long-term tolerance.
• Further research is needed to confirm the asthma-preventive potential of early-life mite AIT.